Abstract | BACKGROUND: Inherent or developed during treatment drug resistance is the main reason for the low effectiveness of chemotherapy in ovarian cancer. IFI16 is a cytoplasmic/ nuclear protein involved in response to virus's infection and cell cycle arrest associated with the cellular senescence. METHODS: Here we performed a detailed IFI16 expression analysis in ovarian cancer cell lines sensitive (A2780) and resistant to doxorubicin (DOX) (A2780DR1 and A2780DR2) and paclitaxel (PAC) (A2780PR1). IFI16 mRNA level, protein level in the nuclear and cytoplasmic fraction (Western blot analysis), the protein expression in cancer cells and nuclei (immunofluorescence analysis) and cancer patient lesions (immunohistochemistry) were performed in this study. RESULTS: We observed upregulation of IFI16 expression in drug resistant cell lines with dominant cytoplasmic localization in DOX-resistant cell lines and nuclear one in the PAC-resistant cell line. The most abundantly overexpressed isoforms of IFI16 were IFI16A and IFI16C. Finally, an analysis of a histological type of ovarian cancer (immunohistochemistry) showed expression in serous ovarian cancer. CONCLUSIONS: Expression of IFI16 in drug-resistant cell lines suggests its role in drug resistance development in ovarian cancer. Expression in serous ovarian cancer suggests its role in the pathogenesis of this histological type.
|
Authors | Justyna Borucka, Karolina Sterzyńska, Dominika Kaźmierczak, Monika Świerczewska, Marta Nowacka, Karolina Wojtowicz, Andrzej Klejewski, Michał Nowicki, Maciej Zabel, Rodryg Ramlau, Radosław Januchowski |
Journal | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
(Biomed Pharmacother)
Vol. 150
Pg. 113036
(Jun 2022)
ISSN: 1950-6007 [Electronic] France |
PMID | 35489285
(Publication Type: Journal Article)
|
Copyright | Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved. |
Chemical References |
- Nuclear Proteins
- Phosphoproteins
- IFI16 protein, human
- Doxorubicin
- Interferon-gamma
- Paclitaxel
|
Topics |
- Carcinoma, Ovarian Epithelial
- Cell Line, Tumor
- Doxorubicin
(pharmacology, therapeutic use)
- Drug Resistance, Neoplasm
(genetics)
- Female
- Humans
- Interferon-gamma
- Nuclear Proteins
(genetics, metabolism)
- Ovarian Neoplasms
(drug therapy, genetics, pathology)
- Paclitaxel
(pharmacology, therapeutic use)
- Phosphoproteins
(metabolism)
|